a2 H1 2026年的牛奶拍打预测,在亚洲销售和产品创新强劲的情况下推动全年展望。 a2 Milk beat forecasts in H1 2026, boosting full-year outlook amid strong Asian sales and product innovation.

a2 牛奶报告头半个2026年收成强劲,净销售额上升18.8%,达到9.926亿新西兰第纳尔,而由中国和其他亚洲市场增长驱动的《欧洲生物贸易协定》潜在的销售额上升近26%。 a2 Milk reported strong first-half 2026 results, with net sales up 18.8% to NZD 992.6 million and underlying EBITDA rising nearly 26%, driven by growth in China and other Asian markets. 该公司将其全年收入增长预测提高到两位数的中位数,并提升了其净利润前景,重申其提前到2026年达到20亿新西兰元年收入的目标。 The company raised its full-year revenue growth forecast to mid double-digit percentages and upgraded its net profit outlook, reaffirming its goal to reach NZD 2 billion in annual revenue by 2026, ahead of schedule. 婴儿配方奶、液体牛奶和A2类新产品系列的强劲性能,在中国销售量增加和运营效率提高的支持下,创世纪和老年人强化粉末的增速促进了增长。 Strong performance in infant formula, liquid milk, and new product lines like a2 Genesis and Seniors fortified powders fueled growth, supported by increased marketing in China and improved operational efficiency. 尽管面临更广泛的人口挑战,包括中国出生率下降,但该公司以创新和战略投资为由,超过了市场趋势。 Despite broader demographic challenges, including declining birth rates in China, the company outpaced market trends, citing innovation and strategic investments. 它宣布每股0.115新西兰第纳尔的临时红利,并在新闻上看到其股票上升9.8%。 It declared an interim dividend of NZD 0.115 per share and saw its shares rise 9.8% on the news.